<?xml version="1.0" encoding="UTF-8"?>
<!-- Version: 1.1.1217.0 -->
<!-- Document created: 18-07-2023 11:03:03 -->
<!-- Created by:  XBRL Wizard, EasyX -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.org/2006/xbrldi http://www.xbrl.org/2006/xbrldi-2006.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:entry="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:arr="http://xbrl.dcca.dk/arr" xmlns:gen="http://xbrl.org/2008/generic" xmlns:tch="http://xbrl.dcca.dk/tch" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:label="http://xbrl.org/2008/label" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:cmn="http://xbrl.dcca.dk/cmn" xmlns:gsd="http://xbrl.dcca.dk/gsd" xmlns:tax="http://xbrl.dcca.dk/tax" xmlns:variable="http://xbrl.org/2008/variable" xmlns:eogs="http://xbrl.dcca.dk/eogs" xmlns:dst="http://xbrl.dcca.dk/dst" xmlns:valm="http://xbrl.org/2010/message/validation" xmlns:msg="http://xbrl.org/2010/message" xmlns:fsa="http://xbrl.dcca.dk/fsa" xmlns:mrv="http://xbrl.dcca.dk/mrv" xmlns:esg="http://xbrl.dcca.dk/esg" xmlns:sob="http://xbrl.dcca.dk/sob" xmlns:tar="http://xbrl.dcca.dk/tar">
  <link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd" />
  <xbrli:context id="ctx1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
        <cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-01</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-01</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
        <cmn:auditorIdentifier>0</cmn:auditorIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">39904276</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
        <cmn:auditorIdentifier>1</cmn:auditorIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:unit id="vDKK">
    <xbrli:measure>iso4217:DKK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <fsa:ClassOfReportingEntity contextRef="ctx1">Regnskabsklasse B</fsa:ClassOfReportingEntity>
  <sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Statement by the Board of Directors and the Executive Board&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:StatementByExecutiveAndSupervisoryBoards>
  <sob:IdentificationOfApprovedAnnualReport contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Bainan Biotech ApS for the financial year 1 January - 31 December 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:IdentificationOfApprovedAnnualReport>
  <sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The annual report is prepared in accordance with the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement>
  <sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January - 31 December 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults>
  <sob:ManagementsStatementAboutManagementsReview contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:ManagementsStatementAboutManagementsReview>
  <sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We recommend that the annual report be approved at the annual general meeting.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting>
  <sob:PlaceOfSignatureOfStatement contextRef="ctx1" xml:lang="da">Copenhagen</sob:PlaceOfSignatureOfStatement>
  <sob:DateOfApprovalOfAnnualReport contextRef="ctx1">2023-07-12</sob:DateOfApprovalOfAnnualReport>
  <gsd:ReportingPeriodStartDate contextRef="ctx1">2022-01-01</gsd:ReportingPeriodStartDate>
  <gsd:ReportingPeriodEndDate contextRef="ctx1">2022-12-31</gsd:ReportingPeriodEndDate>
  <arr:IndependentAuditorsReportsAudit contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Independent auditor's report&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:IndependentAuditorsReportsAudit>
  <arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;To the shareholders of Bainan Biotech ApS&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
  <arr:OpinionOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Opinion&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We have audited the financial statements of Bainan Biotech ApS for the financial year 1 January - 31 December 2022,  which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:OpinionOnAuditedFinancialStatements>
  <arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Basis for opinion&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
  <arr:StatementOnOtherInformationAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Independence&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Material uncertainty related to going concern&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We draw attention to the material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. We refer to note 2 to the financial statements, which states that it is uncertain whether financing of the Company's operations and the necessary investments in the coming years can be secured in due time. However, as Management believes that such financing will be obtained, the financial statements have been prepared on a going concern basis. We have not modified our opinion in respect of this matter.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:StatementOnOtherInformationAuditorsReportOnAuditedFinancialStatements>
  <arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management's responsibilities for the financial statements&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
  <arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Auditor's responsibilities for the audit of the financial statements&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
  <arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Statement on the Management's review&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management is responsible for the Management's review.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
  <arr:SignatureOfAuditorsPlace contextRef="ctx1" xml:lang="da">Copenhagen</arr:SignatureOfAuditorsPlace>
  <arr:SignatureOfAuditorsDate contextRef="ctx1">2023-07-12</arr:SignatureOfAuditorsDate>
  <gsd:NameOfReportingEntity contextRef="ctx1" xml:lang="da">Bainan Biotech ApS</gsd:NameOfReportingEntity>
  <gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx1" xml:lang="da">2200</gsd:AddressOfReportingEntityPostCodeIdentifier>
  <gsd:AddressOfReportingEntityDistrictName contextRef="ctx1" xml:lang="da">København N</gsd:AddressOfReportingEntityDistrictName>
  <gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx1" xml:lang="da">3.</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
  <gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx1">39904276</gsd:IdentificationNumberCvrOfReportingEntity>
  <gsd:DateOfFoundationOfReportingEntity contextRef="ctx1">2019-09-27</gsd:DateOfFoundationOfReportingEntity>
  <gsd:RegisteredOfficeOfReportingEntity contextRef="ctx1" xml:lang="da">København</gsd:RegisteredOfficeOfReportingEntity>
  <gsd:HomepageOfReportingEntity contextRef="ctx1">www.bainanbiotech.com</gsd:HomepageOfReportingEntity>
  <gsd:EmailOfReportingEntity contextRef="ctx1" xml:lang="da">info@bainanbiotech.com</gsd:EmailOfReportingEntity>
  <gsd:TelephoneNumberOfReportingEntity contextRef="ctx1" xml:lang="da">4550552648</gsd:TelephoneNumberOfReportingEntity>
  <gsd:DateOfGeneralMeeting contextRef="ctx1">2023-07-12</gsd:DateOfGeneralMeeting>
  <mrv:ManagementsReview contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management’s review&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:ManagementsReview>
  <mrv:DescriptionOfPrimaryActivitiesOfEntity contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Business review&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The Company operate in research and experimental development within biotechnology, aswell as related activities. The Company’s objective is the research of incretine hormones for the purpose of developing peptide agonists for the treatment of diseases of the human body.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Unusual matters having affected the financial statements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:DescriptionOfPrimaryActivitiesOfEntity>
  <mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Loss of share capital&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The company's assets and liabilities have been assessed with continued operations in mind. Management is aware that the company continues to have capital losses and is thus covered by section 119 of the Danish Companies Act. It is the management's assessment that the company, despite the capital loss, still has the necessary capital base to ensure continued operations. Management continuously assesses the capital base and the need for re-establishment of equity.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management expects to restablishment the share capital through new share capital injections in combination with potential loan conversions to equity.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Going concern&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management monitors its liquidity position on a monthly basis to identify liquidity risks and enable the Board of Directors and Management to prepare for new financing transactions and/or take relevant tactical or strategic actions to allow the company to continue its research and development activities as planned as a going concern.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;As of 31 December 2022, the Company’s available liquidity, comprised of cash and cash equivalents, was DKK 2,748 thousand and total equity was negative DKK 12,544 thousand. For the year ending 31 December 2022, the Company incurred a net loss of DKK 3,129 thousand.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In June 2023, as a result of recent research results in newly performed rodent models, the Board of Directors and Management revisited the company’s corporate strategy and on this basis, measures will be implemented during the remaining part of 2023 to implement a new strategy for establishing preclinical proof-of-concept in a new disease area.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management and the Board of Directors are working to obtain additional sources of funding for the Company in 2023 and believes it is probable that new funding will be obtained in due time to enable the Company to continue its activities as planned.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The company’s ability to continue as a going concern is depending on its ability to raise additional funds. At 31 December 2022, the convertible loan amounted to DKK 7.9 million, and original repayment date was set for July 2023. Subsequent to the balance sheet date, the loan provider confirmed the extension for the loan repayment until 31 December 2024. Therefore, in the annual report 2022, the convertible loan has been presented as short term liability. The current cash position is expected to last through fourth quarter of 2023, which includes the expected tax credit refund of DKK 750 thousand and Management is currently working in securing a loan tranche of DKK 2 million during 2023 which is contingent upon a positive analysis of the current clinical data. Such additional funding is required before 31 December 2023 in order to continue the company´s planned development activities beyond 2023.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;As part of the new strategy, focus will be managing the company’s intellectual property and pursuing business development arrangements, in order to raise a seed round in 2024.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;While these measures are considered likely to ensure that the company will be able to settle its current obligations as they fall due, the company’s ability to settle its non-current obligations including the Covid-19 Syndication loan from Vækstfonden and the Convertible debt facilities is depending on both the company’s ability to realize its studies as well as to raise additional funding in due time.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Due to the uncertainty associated with the outcome of the analysis of the current clinical data, and thereby securing the loan tranche of DKK 2 million, and in longer-term the completion of the financing round, significant uncertainties regarding going concern exist, and therefore the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The Board of Directors and Management believe it is possible to obtain sufficient liquidity in due time during 2023 to enable the company to continue its activities beyond 2023.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Based on this assessment Management has prepared the financial statements presented herein based on assumption of being a going concern.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Reference is made to note 2 for more details.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs>
  <mrv:DescriptionOfNetProfitRelationToExpectedDevelopmentAssumedInPreviousReport contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Financial review&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The income statement for 2022 shows a loss of DKK 3,128,882 against a loss of DKK 9,063,823 last year, and the balance sheet at 31 December 2022 shows a negative equity of DKK 12,543,766.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:DescriptionOfNetProfitRelationToExpectedDevelopmentAssumedInPreviousReport>
  <mrv:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Events after the balance sheet date&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;With reference to section on going concern, the company’s ability to continue as a going concern is depending on its ability to raise additional funds. At 31 December 2022, the convertible loan amounted to DKK 7.9 million, and original repayment date was set for July 2023. Subsequent to the balance sheet date, the loan provider confirmed the extension for the loan repayment until 31 December 2024. Therefore, in the annual report 2022, the convertible loan has been presented as short term liability.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;With reference to section on going concern above, in June 2023, Bainan Biotech received data suggesting an effect of our compounds in the performed rodent models. As a result of these recent research results, the board of directors and management have in June 2023 revisited the company’s corporate strategy and, on this basis, measures will be implemented during the remaining part of 2023 to increase our focus on this area.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;No other events materially affecting the Company's financial position have occurred subsequent to the financial year-end.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod>
  <fsa:OtherOperatingIncome contextRef="ctx1" unitRef="vDKK" decimals="0">928021</fsa:OtherOperatingIncome>
  <fsa:OtherExternalExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">2158201</fsa:OtherExternalExpenses>
  <fsa:GrossResult contextRef="ctx1" unitRef="vDKK" decimals="0">-1230180</fsa:GrossResult>
  <fsa:EmployeeBenefitsExpense contextRef="ctx1" unitRef="vDKK" decimals="0">2089946</fsa:EmployeeBenefitsExpense>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="0">-3320126</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:OtherFinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="0">879655</fsa:OtherFinanceIncome>
  <fsa:OtherFinanceExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">1437931</fsa:OtherFinanceExpenses>
  <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx1" unitRef="vDKK" decimals="0">-3878402</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
  <fsa:TaxExpense contextRef="ctx1" unitRef="vDKK" decimals="0">-749520</fsa:TaxExpense>
  <fsa:ProfitLoss contextRef="ctx1" unitRef="vDKK" decimals="0">-3128882</fsa:ProfitLoss>
  <fsa:TransferredToFromRetainedEarnings contextRef="ctx1" unitRef="vDKK" decimals="0">-3128882</fsa:TransferredToFromRetainedEarnings>
  <fsa:DisclosureOfAccountingPolicies contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Accounting policies&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br&gt;&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Effective from the financial year 2022, the Company has implemented amending act no. 1716 of 27 December 2018 to the Danish Financial Statements Act. The implementation of the amending act has not affected the Company's accounting policies on recognition and measurement of assets and liabilities but has solely entailed a requirement for further disclosures. The accounting policies used in the preparation of the financial statements are consistent with those of last year.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfAccountingPolicies>
  <fsa:InformationOnReportingClassOfEntity contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;The annual report of Bainan Biotech ApS for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:InformationOnReportingClassOfEntity>
  <fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Reporting currency&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;The financial statements are presented in Danish kroner (DKK).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies>
  <fsa:DescriptionOfMethodsOfTranslationOfForeignCurrencies contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Foreign currency translation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfTranslationOfForeignCurrencies>
  <fsa:DescriptionOfAccountingPoliciesRelatedToDerivativeFinancialInstruments contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Derivative financial instruments&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;On initial recognition, derivative financial instruments are recognised at cost in the balance sheet and are subsequently measured at fair value. Positive and negative fair values of derivative financial instruments are presented as separate items in the balance sheet.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfAccountingPoliciesRelatedToDerivativeFinancialInstruments>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIncomeStatementItems contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Income statement&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIncomeStatementItems>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Revenue&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Other operating income&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Other operating income comprise items of a secondary nature relative to the Company's core activities, including gains on the sale of fixed assets.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Government grants are recognized periodically when the work supported by the grant has been reported and presented as other operating income. Government grants are recognized when a final and firm right to the grant has been obtained. Government grants are recognised in the income statement in the same period as the work (external expenses) has been performed as the grants are considered to be reimbursement of research expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Other external expenses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Staff costs&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Staff costs include wages and salaries, including compensated absence and pension to the Company's employees, as well as other social security contributions, etc. The item is net of refunds from public authorities.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Financial income and expenses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Tax&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Income tax of the year comprises refundable tax credits for costs incurred in connection with research and development activities under the Danish Tax Credit Regime.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAssetsAndLiabilities contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Balance sheet&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAssetsAndLiabilities>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Receivables&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Receivables are measured at amortised cost.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Prepayments&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Cash&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Cash comprise bank accounts which are readily convertible into cash and with minor risks of changes in value.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Income taxes&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Income tax receivables are recognized in accordance with the Danish tax credit scheme (Skattekreditordningen). Companies covered by the tax credit scheme may obtain payment of the taxbase of losses originating from research and development expenses of up to DKK 25 million (tax value of DKK 5.5 million).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Liabilities&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;The Company has chosen IAS 39 as interpretation for liabilities.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Financial liabilities comprising amounts payable to credit institutions, trade payables and payables to group entities are recognised at the date of borrowing at cost, corresponding to the proceeds received less transaction costs paid. In subsequent periods, financial liabilities are measured at amortised cost.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Other liabilities are measured at net realisable value.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Debts including government grants&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Loan granted from the government at below the prevailing market interest rate. Loan also includes a bonus element which is considered a non-closely related derivative separated from the host loan contract.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;At initial recognition the loan is measured at fair value computed based on a market interest rate and the bonus element i.e. derivative have been measured at fair value. The difference between the proceeds received and the fair value of the loan including the bonus element is recognized as a government grant. The government grant is recognized as financial income when the conditions attached to the grant have been fulfilled.  Subsequently, the loan is measured at amortized cost and the derivative is measured at fair value through profit and loss. Any gain or loss on the derivative is recognized as financial items.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Convertible loans&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;The convertible debt are initially separated into a debt component and a conversion option. The debt component is measured at amortized cost and the conversion option is measured at fair value through profit or loss.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;The difference between the fair value of the liability component and the total proceeds is allocated to the conversion option. The conversion option is classified as a derivative liability, as it is not convertible into a fixed number of shares for a fixed amount of cash. Subsequent to initial recognition, the conversion option is accounted for as a derivative and thus, it is measured at fair value through profit or loss. Any gains or losses on the conversion option is recognized as part of financial items. The transaction costs are allocated to each component of the loan.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;On initial recognition, derivative financial instruments are recognised at cost in the balance sheet and are subsequently measured at fair value. Positive and negative fair values of derivative financial instruments are presented as separate items in the balance sheet.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeLiabilities contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Deferred income&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Deferred income recognised as a liability comprises payments (from Government grants) received concerning grant income (other operating income) in subsequent financial reporting years.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeLiabilities>
  <fsa:InformationOnSubsequentEvents contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Subsequent events&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;If the company obtains information after the balance sheet date, but prior to the date of the Board of Director’s approval of the financial statements, about conditions that existed at the balance sheet date, the company assesses if the information affects the amounts that it recognizes in the financial statements. The company will adjust the amounts recognized in its financial statements to reflect any adjusting events after the balance sheet date and update the disclosures that relate to those conditions in the light of the new information. For non-adjusting events after the balance sheet date, the company will not change the amounts recognized in its financial statements but will disclose the nature of the non-adjusting event and an estimate of its financial effect, or a statement that such an estimate cannot be made, if applicable.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:InformationOnSubsequentEvents>
  <fsa:ExplanationOfAssumptionsOnWhichChosenCalculationMethodHasBeenBasedForInvestmentsAndBiologicalAssetsMeasuredAtFairValue contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Fair value&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;The fair value measurement is based on the principal market. If no principal market exists, the measurement is based on the most advantageous market, i.e. the market that maximises the price of the asset or liability less transaction and/or transport costs.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;All assets and liabilities which are measured at fair value, or whose fair value is disclosed, are classified based on the fair value hierarchy, see below&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Level 1:Value in an active market for similar assets/liabilities&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Level 2:Value based on recognised valuation methods on the basis of observable market information&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Level 3:Value based on recognised valuation methods and reasonable estimates (non-observable market information).&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;If a reliable fair value cannot be stated according to the above levels, the asset or liability is measured at cost.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:ExplanationOfAssumptionsOnWhichChosenCalculationMethodHasBeenBasedForInvestmentsAndBiologicalAssetsMeasuredAtFairValue>
  <fsa:DisclosureOfUncertaintiesRelatingToGoingConcern contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="2" align="left" valign="middle" &gt;Noter&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;Going concern uncertainties&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;Management monitors its liquidity position on a monthly basis to identify liquidity risks and enable the Board of Directors and Management to prepare for new financing transactions and/or take relevant tactical or strategic actions to allow the company to continue its research and development activities as planned as a going concern.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;In June 2023, as a result of recent research results in newly performed rodent models, the Board of Directors and Management revisited the company’s corporate strategy and on this basis, measures will be implemented during the remaining part of 2023 to implement a new strategy for establishing preclinical proof-of-concept in a new disease area.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;Management and the Board of Directors are working to obtain additional sources of funding for the Company in 2023 and believes it is probable that new funding will be obtained in due time to enable the Company to continue its activities as planned.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;The company’s ability to continue as a going concern is depending on its ability to raise additional funds. At 31 December 2022, the convertible loan amounted to DKK 7.9 million, and original repayment date was set for July 2023. Subsequent to the balance sheet date, the loan provider confirmed the extension for the loan repayment until 31 December 2024. Therefore, in the annual report 2022, the convertible loan has been presented as short term liability. The current cash position is expected to last through fourth quarter of 2023, which includes the expected tax credit refund of DKK 750 thousand and Management is currently working in securing a loan tranche of DKK 2 million during 2023 which is contingent upon a positive analysis of the current clinical data. Such additional funding is required before 31 December 2023 in order to continue the company´s planned development activities beyond 2023.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;As part of the new strategy, focus will be managing the company’s intellectual property and pursuing business development arrangements, in order to raise a seed round in 2024.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;While these measures are considered likely to ensure that the company will be able to settle its current obligations as they fall due, the company’s ability to settle its non-current obligations including the Covid-19 Syndication loan from Vækstfonden and the Convertible debt facilities is depending on both the company’s ability to realize its studies as well as to raise additional funding in due time.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;Due to the uncertainty associated with the outcome of the analysis of the current clinical data, and thereby securing the loan tranche of DKK 2 million, and in longer-term the completion of the financing round, significant uncertainties regarding going concern exist, and therefore the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;The Board of Directors and Management believe it is possible to obtain sufficient liquidity in due time during 2023 to enable the company to continue its activities beyond 2023.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="2%" &gt;&lt;/td&gt;&lt;td width="98%" colspan="1" align="left" valign="middle" &gt;Based on this assessment Management has prepared the financial statements presented herein based on assumption of being a going concern.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfUncertaintiesRelatingToGoingConcern>
  <fsa:DisclosureOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;Events after the balance sheet date&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;With reference to note 2 on going concern, the company’s ability to continue as a going concern is depending on its ability to raise additional funds. At 31 December 2022, the convertible loan amounted to DKK 7.9 million, and original repayment date was set for July 2023. Subsequent to the balance sheet date, the loan provider confirmed the extension for the loan repayment until 31 December 2024. Therefore, in the annual report 2022, the convertible loan has been presented as short term liability.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;With reference to note 2 on going concern above, in June 2023, Bainan Biotech received data suggesting an effect of our compounds in the performed rodent models. As a result of these recent research results, the board of directors and management have in June 2023 revisited the company’s corporate strategy and, on this basis, measures will be implemented during the remaining part of 2023 to increase our focus on this area.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;No other events materially affecting the Company's financial position have occurred subsequent to the financial year-end.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfSignificantEventsOccurringAfterEndOfReportingPeriod>
  <fsa:DisclosureOfOtherOperatingIncome contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="3" align="left" valign="middle" &gt;.Other operating income&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="80%" colspan="1" align="left" valign="middle" &gt;DKK&lt;/td&gt;&lt;td width="11%" align="right" valign="middle" &gt;2022&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;2021&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="80%" colspan="1" align="left" valign="middle" &gt;Goverment grants&lt;/td&gt;&lt;td width="11%" align="right" valign="middle" &gt;928021&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1224456&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="80%" &gt;&lt;/td&gt;&lt;td width="11%" align="right" valign="middle" &gt;928021&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1224456&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="3" align="left" valign="middle" &gt;Government grants relates to reimbursement of research expenses.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfOtherOperatingIncome>
  <fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Staff costs&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfEmployeeBenefitsExpense>
  <fsa:WagesAndSalaries contextRef="ctx1" unitRef="vDKK" decimals="0">2032984</fsa:WagesAndSalaries>
  <fsa:SocialSecurityContributions contextRef="ctx1" unitRef="vDKK" decimals="0">56962</fsa:SocialSecurityContributions>
  <fsa:AverageNumberOfEmployees contextRef="ctx1" unitRef="pure" decimals="0">4</fsa:AverageNumberOfEmployees>
  <fsa:DisclosureOfOtherFinanceIncome contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Financial income&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfOtherFinanceIncome>
  <fsa:OtherAdjustmentsOfFinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="0">0</fsa:OtherAdjustmentsOfFinanceIncome>
  <fsa:ExchangeRateAdjustmentsOtherFinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="0">0</fsa:ExchangeRateAdjustmentsOtherFinanceIncome>
  <fsa:GainsLossesFromCurrentValueAdjustmentsOfFinancialInstrumentsFinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="0">857637</fsa:GainsLossesFromCurrentValueAdjustmentsOfFinancialInstrumentsFinanceIncome>
  <fsa:OtherInterestIncome contextRef="ctx1" unitRef="vDKK" decimals="0">22018</fsa:OtherInterestIncome>
  <fsa:DisclosureOfOtherFinanceExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Financial expenses&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfOtherFinanceExpenses>
  <fsa:OtherInterestExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">1437931</fsa:OtherInterestExpenses>
  <fsa:OtherAdjustmentsOfFinanceExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">0</fsa:OtherAdjustmentsOfFinanceExpenses>
  <fsa:DisclosureOfTaxExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Tax for the year&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br&gt;&lt;br&gt;&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td /&gt;&lt;td&gt;Income tax of the year comprises refundable tax credits for costs incurred in connection with research and development activities under the Danish Tax Credit Regime (LL § 8 X).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfTaxExpenses>
  <fsa:CurrentTaxExpense contextRef="ctx1" unitRef="vDKK" decimals="0">-749520</fsa:CurrentTaxExpense>
  <fsa:DisclosureOfEquity contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;Share capital&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;The Company's share capital has remained DKK 50,000 in the past year.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;At 31 December 2022 the company had lost its share capital. Management will take appropriate measures to restore the share capital.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfEquity>
  <fsa:DisclosureOfLongtermLiabilities contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Borrowings (Other credit institutions)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The Company has taken out the following long-term loan&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" colspan="1" align="left" valign="middle" &gt;DKK&lt;/td&gt;&lt;td width="9%" colspan="1" align="left" valign="middle" &gt;Outstanding nominal amount (DKK)*)&lt;/td&gt;&lt;td width="6%" colspan="1" align="left" valign="middle" &gt;Carrying amount&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;Estimated market interest rate&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;Government grant&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" colspan="1" align="left" valign="middle" &gt;Loan, issued 2020&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;6825000&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;5905013&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;15,00%&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" colspan="1" align="left" valign="middle" &gt;Bonus derivative&lt;/td&gt;&lt;td width="9%" colspan="1" align="left" valign="middle" &gt;-&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;-&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" &gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;6825000&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;5905013&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;-&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;*) Including embedded governmental grant of DKK 2,420,875&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The Company secured in December 2020 a Covid-19 Syndication loan from Vækstfonden which includes a government grant in terms of an interest discount.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The loan includes the following terms: • Term: 72 months from issuance – repayment begins after 36 months. • Interest coupon CIBOR 3 Month + 5% accruing over the term of the loan • Loan principal: DKK 6,825,000 (Including embedded governmental grant of DKK 2,420,875) • Lender bonus element, where the principal under certain conditions are doubled. The bonus element is accounted for as a non-closely related derivative.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;If the Company´s shares are transferred for a gross proceeds per share, which is more than four times (4x) as high as the price per share in connection with the Convertible debt facilities (a "Qualified Sale"). The Company shall pay the Lender a bonus equal to the Principal (the "Bonus") (less interest payments made during the period until time of the bonus). The Bonus shall not be paid, insofar the gross proceeds per share does not constitute a Qualified Sale.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;This valuation method requires Management to make certain assumptions regarding a potential Qualified Sale. Management estimated the fair value of the Bonus derivative to 0 as of 31 December 2022.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Interest expenses for the year amounts to DKK 808,548.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;A government grant of DKK 2,420,875 was recognised for during 2020 at the inception of the loan.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br&gt;&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Convertible debt facilities and Conversion option&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The Company has the following Convertible debt facilities and Conversion option&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" colspan="1" align="left" valign="middle" &gt;DKK&lt;/td&gt;&lt;td width="9%" colspan="1" align="left" valign="middle" &gt;Outstanding nominal amount&lt;/td&gt;&lt;td width="6%" colspan="1" align="left" valign="middle" &gt;Carrying amount of Loan&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;Carrying amount of Embedded derivative&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;Estimated market interest rate&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" colspan="1" align="left" valign="middle" &gt;Loan tranche 1, issued 2020&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;6700000&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;6711963&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;1677991&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;21,64%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" colspan="1" align="left" valign="middle" &gt;Loan tranche 2, issued 2022&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1300000&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;1181328&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;295332&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;19,26%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="65%" &gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;8000000&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;7893291&lt;/td&gt;&lt;td width="10%" align="right" valign="middle" &gt;1973323&lt;/td&gt;&lt;td width="10%" colspan="1" align="left" valign="middle" &gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The Company obtained a convertible loan at 1 August 2020. The principal amount of the Loan is DKK 10,000,000 and is designed to be disbursed to the Company in three tranches, whereas the first tranche of DKK 6,700,000 was disbursed on 1 August 2020, and the second tranche disbursed DKK 1,300,000 on 11 April 2022. Any disbursements are subject to several conditions based on different milestones as set out in the loan note.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The loan matures on 10 July 2023 and has an embedded interest of 8% p.a. Reference is made to note 3 regarding extension of the repayment schedule.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The Lender has an option to convert the loan amount into shares in the Company with a conversion discount of 20% to the share price of the Company and can be converted in the event of a Qualified Financing, in the event of an Exit or at maturity date.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The convertible debt was initially separated into a debt component and a conversion option. The difference between the fair value of the liability component and the total proceeds is allocated to the conversion option. The conversion option is classified as a derivative liability. Subsequent to initial recognition, the conversion option is accounted for as a derivative and thus, it has been measured at fair value through profit or loss as part of financial items.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Fair value as at 31 December 2022 of the conversion option has been based on the key assumption that a qualified financing activity is expected to take place in 2024.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;A fair value adjustment of DKK 857,637 has been recognized through the income statement during 2022.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfLongtermLiabilities>
  <fsa:DisclosureOfContingentLiabilities contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;Contractual obligations and contingencies, etc.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;Other financial obligations&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;The Company has not provided any security or other collateral in assets at 31 December 2022.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;As stated in note 10, the loan that the company entered into in 2020 contains a bonus element, where the principal under certain conditions is doubled (less already paid interest). This valuation method requires Management to make certain assumptions. Management has estimated the fair value of the Bonus derivative to 0 as of 31 December 2022.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfContingentLiabilities>
  <fsa:DisclosureOfCollateralsAndAssetsPledgesAsSecurity contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;Collateral&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;The Company has not provided any security or other collateral in assets at 31 December 2022.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfCollateralsAndAssetsPledgesAsSecurity>
  <gsd:InformationOnTypeOfSubmittedReport contextRef="ctx1">Årsrapport</gsd:InformationOnTypeOfSubmittedReport>
  <gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx1">30700228</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
  <gsd:NameOfSubmittingEnterprise contextRef="ctx1" xml:lang="da">EY Godkendt Revisionspartnerselskab</gsd:NameOfSubmittingEnterprise>
  <gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx1" xml:lang="da">Cortex Park Vest 3</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
  <gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx1" xml:lang="da">5230 Odense M</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
  <gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx1" xml:lang="da">xWizard version 1.1.1217.0, by EasyX Aps. www.easyx.eu</gsd:ToolForPreparingTheXBRLInstanceDocument>
  <gsd:PrecedingReportingPeriodStartDate contextRef="ctx1">2021-01-01</gsd:PrecedingReportingPeriodStartDate>
  <gsd:PredingReportingPeriodEndDate contextRef="ctx1">2021-12-31</gsd:PredingReportingPeriodEndDate>
  <cmn:TypeOfAuditorAssistance contextRef="ctx1">Revisionspåtegning</cmn:TypeOfAuditorAssistance>
  <arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1">Grundlag for konklusion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
  <arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1">Konklusion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
  <gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx1" xml:lang="da">Bolette Hartmann</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
  <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx2" xml:lang="da">Bolette Hartmann</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Mette Marie Rosenkilde</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Chair</cmn:TitleOfMemberOfSupervisoryBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx4" xml:lang="da">Jens Juul Holst</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx5" xml:lang="da">Bolette Hartmann</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <fsa:OtherOperatingIncome contextRef="ctx6" unitRef="vDKK" decimals="0">1224456</fsa:OtherOperatingIncome>
  <fsa:OtherExternalExpenses contextRef="ctx6" unitRef="vDKK" decimals="0">4934258</fsa:OtherExternalExpenses>
  <fsa:GrossResult contextRef="ctx6" unitRef="vDKK" decimals="0">-3709802</fsa:GrossResult>
  <fsa:EmployeeBenefitsExpense contextRef="ctx6" unitRef="vDKK" decimals="0">4959288</fsa:EmployeeBenefitsExpense>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx6" unitRef="vDKK" decimals="0">-8669090</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:OtherFinanceIncome contextRef="ctx6" unitRef="vDKK" decimals="0">302402</fsa:OtherFinanceIncome>
  <fsa:OtherFinanceExpenses contextRef="ctx6" unitRef="vDKK" decimals="0">2267219</fsa:OtherFinanceExpenses>
  <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx6" unitRef="vDKK" decimals="0">-10633907</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
  <fsa:TaxExpense contextRef="ctx6" unitRef="vDKK" decimals="0">-1570084</fsa:TaxExpense>
  <fsa:ProfitLoss contextRef="ctx6" unitRef="vDKK" decimals="0">-9063823</fsa:ProfitLoss>
  <fsa:TransferredToFromRetainedEarnings contextRef="ctx6" unitRef="vDKK" decimals="0">-9063823</fsa:TransferredToFromRetainedEarnings>
  <fsa:WagesAndSalaries contextRef="ctx6" unitRef="vDKK" decimals="0">4894894</fsa:WagesAndSalaries>
  <fsa:SocialSecurityContributions contextRef="ctx6" unitRef="vDKK" decimals="0">64394</fsa:SocialSecurityContributions>
  <fsa:AverageNumberOfEmployees contextRef="ctx6" unitRef="pure" decimals="0">9</fsa:AverageNumberOfEmployees>
  <fsa:OtherAdjustmentsOfFinanceIncome contextRef="ctx6" unitRef="vDKK" decimals="0">300000</fsa:OtherAdjustmentsOfFinanceIncome>
  <fsa:ExchangeRateAdjustmentsOtherFinanceIncome contextRef="ctx6" unitRef="vDKK" decimals="0">2402</fsa:ExchangeRateAdjustmentsOtherFinanceIncome>
  <fsa:GainsLossesFromCurrentValueAdjustmentsOfFinancialInstrumentsFinanceIncome contextRef="ctx6" unitRef="vDKK" decimals="0">0</fsa:GainsLossesFromCurrentValueAdjustmentsOfFinancialInstrumentsFinanceIncome>
  <fsa:OtherInterestIncome contextRef="ctx6" unitRef="vDKK" decimals="0">0</fsa:OtherInterestIncome>
  <fsa:OtherInterestExpenses contextRef="ctx6" unitRef="vDKK" decimals="0">1956857</fsa:OtherInterestExpenses>
  <fsa:OtherAdjustmentsOfFinanceExpenses contextRef="ctx6" unitRef="vDKK" decimals="0">310362</fsa:OtherAdjustmentsOfFinanceExpenses>
  <fsa:CurrentTaxExpense contextRef="ctx6" unitRef="vDKK" decimals="0">-1570084</fsa:CurrentTaxExpense>
  <fsa:ShorttermTaxReceivables contextRef="ctx7" unitRef="vDKK" decimals="0">749403</fsa:ShorttermTaxReceivables>
  <fsa:OtherShorttermReceivables contextRef="ctx7" unitRef="vDKK" decimals="0">210138</fsa:OtherShorttermReceivables>
  <fsa:ShorttermReceivables contextRef="ctx7" unitRef="vDKK" decimals="0">959541</fsa:ShorttermReceivables>
  <fsa:CashAndCashEquivalents contextRef="ctx7" unitRef="vDKK" decimals="0">2748331</fsa:CashAndCashEquivalents>
  <fsa:CurrentAssets contextRef="ctx7" unitRef="vDKK" decimals="0">3707872</fsa:CurrentAssets>
  <fsa:Assets contextRef="ctx7" unitRef="vDKK" decimals="0">3707872</fsa:Assets>
  <fsa:ContributedCapital contextRef="ctx7" unitRef="vDKK" decimals="0">50000</fsa:ContributedCapital>
  <fsa:RetainedEarnings contextRef="ctx7" unitRef="vDKK" decimals="0">-12593766</fsa:RetainedEarnings>
  <fsa:Equity contextRef="ctx7" unitRef="vDKK" decimals="0">-12543766</fsa:Equity>
  <fsa:LongtermDebtToOtherCreditInstitutions contextRef="ctx7" unitRef="vDKK" decimals="0">5905013</fsa:LongtermDebtToOtherCreditInstitutions>
  <fsa:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstruments contextRef="ctx7" unitRef="vDKK" decimals="0">0</fsa:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstruments>
  <fsa:LongtermLiabilitiesOtherThanProvisions contextRef="ctx7" unitRef="vDKK" decimals="0">5905013</fsa:LongtermLiabilitiesOtherThanProvisions>
  <fsa:ConvertibleProfitYieldingOrDividendYieldingShorttermDebtInstruments contextRef="ctx7" unitRef="vDKK" decimals="0">9866614</fsa:ConvertibleProfitYieldingOrDividendYieldingShorttermDebtInstruments>
  <fsa:ShorttermPrepaymentsReceivedFromCustomers contextRef="ctx7" unitRef="vDKK" decimals="0">0</fsa:ShorttermPrepaymentsReceivedFromCustomers>
  <fsa:ShorttermTradePayables contextRef="ctx7" unitRef="vDKK" decimals="0">468227</fsa:ShorttermTradePayables>
  <fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx7" unitRef="vDKK" decimals="0">11784</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
  <fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx7" unitRef="vDKK" decimals="0">10346625</fsa:ShorttermLiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesOtherThanProvisions contextRef="ctx7" unitRef="vDKK" decimals="0">16251638</fsa:LiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesAndEquity contextRef="ctx7" unitRef="vDKK" decimals="0">3707872</fsa:LiabilitiesAndEquity>
  <fsa:ShorttermTaxReceivables contextRef="ctx8" unitRef="vDKK" decimals="0">1579084</fsa:ShorttermTaxReceivables>
  <fsa:OtherShorttermReceivables contextRef="ctx8" unitRef="vDKK" decimals="0">444386</fsa:OtherShorttermReceivables>
  <fsa:ShorttermReceivables contextRef="ctx8" unitRef="vDKK" decimals="0">2023470</fsa:ShorttermReceivables>
  <fsa:CashAndCashEquivalents contextRef="ctx8" unitRef="vDKK" decimals="0">3622350</fsa:CashAndCashEquivalents>
  <fsa:CurrentAssets contextRef="ctx8" unitRef="vDKK" decimals="0">5645820</fsa:CurrentAssets>
  <fsa:Assets contextRef="ctx8" unitRef="vDKK" decimals="0">5645820</fsa:Assets>
  <fsa:ContributedCapital contextRef="ctx8" unitRef="vDKK" decimals="0">50000</fsa:ContributedCapital>
  <fsa:RetainedEarnings contextRef="ctx8" unitRef="vDKK" decimals="0">-9464884</fsa:RetainedEarnings>
  <fsa:Equity contextRef="ctx8" unitRef="vDKK" decimals="0">-9414884</fsa:Equity>
  <fsa:LongtermDebtToOtherCreditInstitutions contextRef="ctx8" unitRef="vDKK" decimals="0">5096466</fsa:LongtermDebtToOtherCreditInstitutions>
  <fsa:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstruments contextRef="ctx8" unitRef="vDKK" decimals="0">7051598</fsa:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstruments>
  <fsa:LongtermLiabilitiesOtherThanProvisions contextRef="ctx8" unitRef="vDKK" decimals="0">12148064</fsa:LongtermLiabilitiesOtherThanProvisions>
  <fsa:ConvertibleProfitYieldingOrDividendYieldingShorttermDebtInstruments contextRef="ctx8" unitRef="vDKK" decimals="0">1762899</fsa:ConvertibleProfitYieldingOrDividendYieldingShorttermDebtInstruments>
  <fsa:ShorttermPrepaymentsReceivedFromCustomers contextRef="ctx8" unitRef="vDKK" decimals="0">310021</fsa:ShorttermPrepaymentsReceivedFromCustomers>
  <fsa:ShorttermTradePayables contextRef="ctx8" unitRef="vDKK" decimals="0">506982</fsa:ShorttermTradePayables>
  <fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="ctx8" unitRef="vDKK" decimals="0">332738</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
  <fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx8" unitRef="vDKK" decimals="0">2912640</fsa:ShorttermLiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesOtherThanProvisions contextRef="ctx8" unitRef="vDKK" decimals="0">15060704</fsa:LiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesAndEquity contextRef="ctx8" unitRef="vDKK" decimals="0">5645820</fsa:LiabilitiesAndEquity>
  <fsa:Equity contextRef="ctx9" unitRef="vDKK" decimals="0">50000</fsa:Equity>
  <fsa:Equity contextRef="ctx10" unitRef="vDKK" decimals="0">-9464884</fsa:Equity>
  <fsa:Equity contextRef="ctx11" unitRef="vDKK" decimals="0">-9414884</fsa:Equity>
  <fsa:ProfitLoss contextRef="ctx12" unitRef="vDKK" decimals="0">0</fsa:ProfitLoss>
  <fsa:ProfitLoss contextRef="ctx13" unitRef="vDKK" decimals="0">-3128882</fsa:ProfitLoss>
  <fsa:Equity contextRef="ctx14" unitRef="vDKK" decimals="0">50000</fsa:Equity>
  <fsa:Equity contextRef="ctx15" unitRef="vDKK" decimals="0">-12593766</fsa:Equity>
  <cmn:NameOfAuditFirm contextRef="ctx16" xml:lang="da">EY Godkendt Revisionspartnerselskab</cmn:NameOfAuditFirm>
  <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx16">30700228</cmn:IdentificationNumberCvrOfAuditFirm>
  <cmn:NameAndSurnameOfAuditor contextRef="ctx16" xml:lang="da">Birgit Morville Schrøder</cmn:NameAndSurnameOfAuditor>
  <cmn:DescriptionOfAuditor contextRef="ctx16" xml:lang="da">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
  <cmn:IdentificationNumberOfAuditor contextRef="ctx16">mne21337</cmn:IdentificationNumberOfAuditor>
  <cmn:NameAndSurnameOfAuditor contextRef="ctx17" xml:lang="da">Anders Roe Eriksen</cmn:NameAndSurnameOfAuditor>
  <cmn:DescriptionOfAuditor contextRef="ctx17" xml:lang="da">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
  <cmn:IdentificationNumberOfAuditor contextRef="ctx17">mne46667</cmn:IdentificationNumberOfAuditor>
  <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx17">30700228</cmn:IdentificationNumberCvrOfAuditFirm>
  <cmn:NameOfAuditFirm contextRef="ctx17" xml:lang="da">EY Godkendt Revisionspartnerselskab</cmn:NameOfAuditFirm>
</xbrli:xbrl>